MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb (NCT04649359)
MAGNETISMM-3 AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 2 STUDY OF ELRANATAMAB (PF-06863135) MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY
🩺 Plain-English Summary (8th-Grade Level)
The purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.
Who can join: Review the eligibility criteria below.
Location: Beverly Hills Cancer Center — Beverly Hills, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (40 Sites)
Showing the first 25 of 40 sites.
- Beverly Hills Cancer Center — Beverly Hills, California
- Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- UCLA Hematology/Oncology Clinic — Los Angeles, California
- UC Irvine Health - Chao Family Comprehensive Cancer Center — Orange, California
- Baptist Hospital of Miami — Miami, Florida
- Miami Cancer Institute — Miami, Florida
- Emory University — Atlanta, Georgia
- Winship Cancer Institute, Emory University — Atlanta, Georgia
- Blood and Marrow Transplant Group of Georgia — Atlanta, Georgia
- Northwestern Medical Group — Chicago, Illinois
- Northwestern Memorial Hospital — Chicago, Illinois
- Loyola University Chicago performing research at Loyola University Medical Center — Maywood, Illinois
- Loyola University Medical Center — Maywood, Illinois
- Norton Women's and Children's Hospital — Louisville, Kentucky
- Ochsner Clinic Foundation — New Orleans, Louisiana
- Regional Cancer Care Associates, LLC — Hackensack, New Jersey
- Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy — Long Island City, New York
- Weill Cornell Medical College - New York Presbyterian Hospital — New York, New York
- Weill Cornell Medical College - New York Presbyterian Hospital — New York, New York
- St Francis Physician Services Inc — Greenville, South Carolina
- Baylor Scott & White Research Institute — Dallas, Texas
- St Vincent's Hospital (Melbourne) — Fitzroy, Victoria
- The Alfred — Melbourne, Victoria
- Epworth Healthcare — Richmond, Victoria
- CIUSSS-EMTL, Installation Hopital Maisonneuve-Rosemont — Montreal, Quebec
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Myeloma
- Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
- Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
- A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey
Explore by condition: All Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.